ZENA THERAPEUTICS INC.

PRINCETON, NJ · Founded 2021 · Biotech · Private

Novel synthetic GABAAR partial agonist molecules (lead: RU-EC2-118) for anxiety treatment in opioid use disorder

Claim this profile

Follows are private to you and power your alerts

Updated · zenatherapeutics.com

Sector
Biotech
Headquarters
PRINCETON, NJ
Founded
2021
Latest Form D
$500K, Sep 2023
Total capital
$868K
Federal grants
$368K
2 awards · 2023–2024
Rank in peer group#396 of 502
Private capital raised
$500K
1 Form D · last Sep 2023
38 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

20232024FEDERAL ↑EQUITY ↓Cumulative $868K$313K$55K1st Form D$500K
20232024FEDERAL ↑EQUITY ↓Cumulative $868K$313K$55K1st Form D$500K

Latest events

  • Federal grantHealth and Human S · Phase I · Development of compound RUEC2-118, a novel partial GABAAR positive modulator, a fast-acting treatment for general anxiety and panic disorder, to prevent opioid and benzodiazepine overdose fatalities.$55K
  • Private capital raisedForm D · SEC · 1st filing$500K
  • Federal grantHealth and Human S · Phase I · Development of compound RUEC2-118, a novel partial GABAAR positive modulator, a fast-acting treatment for general anxiety and panic disorder, to prevent opioid and benzodiazepine overdose fatalities.$313K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

4months

from ZENA THERAPEUTICS INC.’s first federal award to its first private round.

First federal award · Apr 2023
Health and Human S · $313K
First Form D · Sep 2023
$500K · 1st Form D
Awards before first raise
1 award

An association in public records, not a cause or a prediction.

Standing among 502 peers

Line = median

Biotech · Molecule

  • Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Eileen CarryResearcherExecutive Officer, DirectorLinked by $368K in grants as PI
  • Ariane VasilatisExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • ALLANDER BIOTECHNOLOGIES, INC.Similar federal contract value in Biotech · null in contracts
  • WinSanTor, Inc.Similar federal contract value in Biotech · null in contracts
  • Kioga Inc.Similar federal contract value in Biotech · null in contracts
  • SYNLIFE INCSimilar federal contract value in Biotech · null in contracts
  • KINARX, INCSimilar federal contract value in Biotech · null in contracts
  • KNOUBIS BIO, INC.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .